Foren & Soziale Netzwerke zur ABEONA THERAPEUTICS Aktie

 

Kursziel: 17.158 €

Kursziel: 17.112 €

Kursziel: 16.7105 €

Kursziel: 17.854 €

Looks like a good monthly or longer play for the following reasons: 1. Beginning to see elevated RVOL (although it is Pre) in the hundreds. 2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter). 3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between) 4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years. 5. Post RS, the price has trended slowly up, with higher lows, and

Looks like a good monthly or longer play for the following reasons: 1. Beginning to see elevated RVOL (although it is Pre) in the hundreds. 2. recent fantastic news, the MAIN drug they are developing received FDA approval, this cannot be understated as a) it makes all previous revenues from quarters irrelevant (as they can now fully market and distribute the treatment, which will fix prior low rev issues, because its an R&D company), b) they were only losing about 40mil a quarter before which again, is actually relatively low compared to other pharma-dev companies (many have like 20mil + burn per quarter). 3. stock is trading at a consolidation region below the gap, for the last few years. (avg range between 3-5$, with some spikes between) 4. managed to stay in the NASDAQ due to a 25/1 reverse split, which many times just continues to crush the company stock, but this one has held steadfast in this lower region for the last three years. 5. Post RS, the price has trended slowly up, with higher lows, and

Kursziel: -

Kursziel: 6.0 €

Kursziel: -

Kursziel: -

Kursziel: 13.8555 €

Kursziel: -

Kursziel: 14.373 €